Data Insights

Jaktinib hydrochloride by Suzhou Zelgen Biopharmaceutical for Alopecia Areata: Likelihood of Approval

Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase I for Alopecia Areata. According to...

Data Insights

Jaktinib hydrochloride by Suzhou Zelgen Biopharmaceutical for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval

Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase III for Post-Essential Thrombocythemia Myelofibrosis (Post-ET...

Data Insights

Jaktinib hydrochloride by Suzhou Zelgen Biopharmaceutical for Post-Polycythemia Vera Myelofibrosis (PPV-MF): Likelihood of Approval

Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase III for Post-Polycythemia Vera Myelofibrosis (PPV-MF)....

Data Insights

Jaktinib hydrochloride by Suzhou Zelgen Biopharmaceutical for Ankylosing Spondylitis (Bekhterev's Disease): Likelihood of Approval

Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase III for Ankylosing Spondylitis (Bekhterev's Disease)....

Data Insights

Donafenib tosylate by Suzhou Zelgen Biopharmaceutical for Endometrial Cancer: Likelihood of Approval

Donafenib tosylate is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase I for Endometrial Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Donafenib Tosylate in Endometrial Cancer

Data Insights

Donafenib tosylate by Suzhou Zelgen Biopharmaceutical for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

Donafenib tosylate is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma)....

Likelihood of Approval and Phase Transition Success Rate Model - Donafenib Tosylate in Bile Duct Cancer (Cholangiocarcinoma)

Data Insights

Donafenib tosylate by Suzhou Zelgen Biopharmaceutical for Hepatocellular Carcinoma: Likelihood of Approval

Donafenib tosylate is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase II for Hepatocellular Carcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Donafenib Tosylate in Hepatocellular Carcinoma

Data Insights

Jaktinib hydrochloride by Suzhou Zelgen Biopharmaceutical for Rheumatoid Arthritis: Likelihood of Approval

Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase II for Rheumatoid Arthritis. According to...

Data Insights

Donafenib tosylate by Suzhou Zelgen Biopharmaceutical for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Donafenib tosylate is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase I for Head And Neck Squamous...

Likelihood of Approval and Phase Transition Success Rate Model - Donafenib Tosylate in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Donafenib tosylate by Suzhou Zelgen Biopharmaceutical for Solid Tumor: Likelihood of Approval

Donafenib tosylate is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase I for Solid Tumor. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Donafenib Tosylate in Solid Tumor

Data Insights

Jaktinib hydrochloride by Suzhou Zelgen Biopharmaceutical for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis): Likelihood of Approval

Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase II for Chronic Idiopathic Myelofibrosis (Primary...

Data Insights

Jaktinib hydrochloride by Suzhou Zelgen Biopharmaceutical for Ankylosing Spondylitis (Bekhterev's Disease): Likelihood of Approval

Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase III for Ankylosing Spondylitis (Bekhterev's Disease)....

Likelihood of Approval and Phase Transition Success Rate Model - Jaktinib Hydrochloride in Ankylosing Spondylitis (Bekhterev's Disease)

Data Insights

Jaktinib hydrochloride by Suzhou Zelgen Biopharmaceutical for Post-Polycythemia Vera Myelofibrosis (PPV-MF): Likelihood of Approval

Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase III for Post-Polycythemia Vera Myelofibrosis (PPV-MF)....

Likelihood of Approval and Phase Transition Success Rate Model - Jaktinib Hydrochloride in Post-Polycythemia Vera Myelofibrosis (PPV-MF)